Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

496
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
496
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Scaled Multidimensional Assays of Variant Effect Identify Sequence-Function Relationships in Hypertrophic Cardiomyopathy.

Circulation·2026
Same author

Autonomous biomedical research with an artificial intelligence agent.

Science (New York, N.Y.)·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Artificial Intelligence-Enabled Cardiac Function Estimation from Phone Videos of Echocardiograms.

medRxiv : the preprint server for health sciences·2026
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Population-scale detection of methylation outliers from long-read genome sequencing.

medRxiv : the preprint server for health sciences·2026

相关实验视频

Updated: Jul 13, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

在非β阻塞R- 乙基卡维迪醇的高性心肌病中改善心脏功能和减小心律不整

Kinya Seo1, Yuta Yamamoto1, Anna Kirillova1

  • 1From the Departments of Medicine (K.S., Y.Y., A.K., M.K., S.Y., Y.H., Q.W., M.V.P., M.T.W., V.N.P., E.A.A.), Stanford University School of Medicine, CA.

Circulation
|October 18, 2023
PubMed
概括

一种新型治疗药物R- carvedilol有效抑制高收缩性心肌病 (HCM) 模型中的心律失常. 这种药物可以改善心率而不会降低心率,为HCM患者提供独特的治疗选择.

关键词:
心肌病,高性卡维迪洛尔酸受体释放通道

更多相关视频

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

654

相关实验视频

Last Updated: Jul 13, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

654

科学领域:

  • 心脏病学
  • 药理学
  • 遗传学

背景情况:

  • 超缩性心肌病 (HCM) 具有超缩性和心律失常的特征,而β阻塞剂是第一线治疗.
  • 目前的β抑制剂可能会导致心脏输出减少和疲劳等不良影响.
  • 马瓦卡门在超收缩性方面具有前景,但仅限于特定的患者群体,其抗心律失常作用尚不清楚.

研究的目的:

  • 查β阻塞剂对肌细胞收缩性和抗失常性能的影响.
  • 在HCM小鼠模型中评估有前途的药物的体内疗效.
  • 将已确定药物的疗效与现有的HCM疗法进行比较.

主要方法:

  • 检查了21种β-阻断剂对肌细胞收缩性和抗失常性能的影响.
  • 在已确定的HCM小鼠模型中使用血液动力学压力-体积循环分析评估心脏功能.
  • 在体外和体内使用患者衍生的iPSC心肌细胞对甲醇,维拉帕米尔和mavacamten进行了疗效测试.

主要成果:

  • 卡维迪洛尔是一种非典型的贝塔阻断剂,通过抑制RyR2来抑制收缩功能和心律失常.
  • 卡维迪醇的R- 反体抑制了RyR2和α1- 上腺体受体,降低了收缩性,但没有降低心率或心率.
  • 与现有疗法相比,R- carvedilol在小鼠和iPSC模型中表现出更高的疗效,可以使高动力收缩正常化,抑制心律失常,并增加心脏输出量.

结论:

  • 通过对α1-上腺素受体和RyR2的双重阻断,R-上腺素减弱了高动力收缩并抑制了心律失常.
  • 这种双重作用可以改善心率,而不会降低心率,这是HCM的独特治疗特征.
  • R- carvedilol可能有利于HCM患者,特别是那些没有左心室外流通道阻塞的患者.